Stock SGMO SANGAMO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Sangamo Therapeutics, Inc.

Equities

SGMO

US8006771062

Real-time Estimate Cboe BZX
Other stock markets
 01:11:56 2024-06-11 pm EDT 		5-day change 1st Jan Change
0.603 USD +4.33% Intraday chart for Sangamo Therapeutics, Inc. +7.29% +12.09%
May. 14 Transcript : Sangamo Therapeutics, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 08:30 AM
May. 09 Transcript : Sangamo Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sangamo: Q1 Earnings Snapshot
AQ
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
BU
Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
BU
Sangamo Therapeutics : ASGCT 2024
PU
Sangamo Therapeutics : Site-directed integration of large DNA sequences into endogenous sites in the human genome using engineered Modular Integrases (MINTS)
PU
Sangamo Therapeutics : Widespread CNS Tau Knockdown for the Potential Treatment of Alzheimer’s Disease and other Tauopathies
PU
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
BU
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data from Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting
AQ
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
BU
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
AQ
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
BU
Sangamo: Q4 Earnings Snapshot
AQ
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
BU
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
BU
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
BU
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
BU
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
BU
Sangamo Therapeutics : Corporate Presentation
PU
Sangamo: Q3 Earnings Snapshot
AQ
Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SGMO Stock
  4. News Sangamo Therapeutics, Inc.
  5. Press Releases